Drug

Naltrexone

In clinical development

ClassOpioid receptors; mu/kappa/delta antagonistEmerging researchLate-stage developmentSteady momentum

Also known as Contrave, Depade, Embeda, N-Cyclopropylmethyl-14-hydroxydihydromorphinone+8 more

Contrave, Depade, Embeda, N-Cyclopropylmethyl-14-hydroxydihydromorphinone, N-Cyclopropylmethylnoroxymorphone, ReVia, Vivitrol, Naltrexon, Naltrexona, 17-(Cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxymorphinan-6-one, Naltrexone Hydrochloride, Naltrexonum.

RxNorm7243 ChEMBLCHEMBL19019 ATCN07BB04UNII5S6W795CQM

Research papers

Active clinical trials

Protein targets

Latest activity

beta

Recent clinical, regulatory, research and industry developments relating to this drug.

Low Dose Naltrexone (LDN) Therapy for Complex Regional Pain Syndrome (CRPS): A Feasibility Study

Clinical trial2026-08-01Primary completion · ClinicalTrials.gov

A Multiple Health Behavior Change Intervention for Weight Loss and Smoking Cessation for Pre-Bariatric Surgery Patients

Clinical trial2026-07-08Results expected Q4 2030 · ClinicalTrials.gov

A Randomized, Double-Blinded Clinical Trial to Evaluate the Effectiveness of Naltrexone in Improving Nonsuicidal Self-Injurious Behavior

Clinical trial2026-06-11Results expected Q4 2027 · ClinicalTrials.gov

A Randomized, Double-Blinded Clinical Trial to Evaluate the Effects of Naltrexone in Improving Nonsuicidal Self-injurious Behavior

Clinical trial2026-05-22Results expected Q1 2027 · ClinicalTrials.gov

ImmuneNet: Quantum-Synaptic Immunotherapy Mapping

Clinical trial2026-05-22Results expected Q4 2034 · ClinicalTrials.gov

Low-dose Naltrexone (LDN) for the Treatment of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS): Dose-Finding

Clinical trial2026-05-14Results expected Q2 2028 · ClinicalTrials.gov

A Sequential Dose Cohort Pharmacokinetic and Safety Study of Implantable Long-Acting Naltrexone Subcutaneous Pellets With or Without Bupropion Compared to Naltrexone IM Injection (Vivitrol®) in Healthy Normal Volunteers

Clinical trial2026-05-13Results expected Q4 2026 · ClinicalTrials.gov

Preliminary Safety and Efficacy of Semaglutide and Naltrexone Combination Therapy for Alcohol Use Disorder

Clinical trial2026-05-12Results expected Q3 2028 · ClinicalTrials.gov

Naltrexone/bupropion for binge-eating disorder: A randomized, double-blind, placebo-controlled trial.

Research2023-09-26Obesity (Silver Spring, Md.)

Randomized, proof-of-concept trial of low dose naltrexone for patients with breakthrough symptoms of major depressive disorder on antidepressants.

Research2016-10-01Journal of affective disorders

Naltrexone vs Placebo for the Treatment of Alcohol Dependence: A Randomized Clinical Trial.

Research2015-05-01JAMA psychiatry

Naltrexone for impulse control disorders in Parkinson disease: a placebo-controlled study.

Research2014-07-18Neurology

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name

Naltrexone

Aliases & brands

ContraveDepadeEmbedaN-Cyclopropylmethyl-14-hydroxydihydromorphinoneN-CyclopropylmethylnoroxymorphoneReViaVivitrolNaltrexonNaltrexona17-(Cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxymorphinan-6-oneNaltrexone HydrochlorideNaltrexonum

RxNorm CUI

7243

ChEMBL ID

CHEMBL19019

ATC codes

N07BB04

UNII

5S6W795CQM

Primary mechanism

Opioid receptors; mu/kappa/delta antagonist

Pharmacology & targets

3 targets

Known molecular targets and mechanisms supported by curated pharmacology databases.

Mu-type opioid receptor

OPRM1 · P35372

ANTAGONISTOpioid receptors; mu/kappa/delta antagonist

Kappa-type opioid receptor

OPRK1 · P41145

ANTAGONISTOpioid receptors; mu/kappa/delta antagonist

Delta-type opioid receptor

OPRD1 · P41143

ANTAGONISTOpioid receptors; mu/kappa/delta antagonist

Clinical trials

187 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme

CLINICALTRIALS.GOV · LIVE REGISTRY

187

registered trials across all phases

LATEST COMPLETION 2026

Active studies

Recruiting

Late-stage (III+)

132

Completed

Discontinued

PHASE DISTRIBUTIONn = 187

Early Phase 16Phase 117Phase 1 / 210Phase 266Phase 2 / 37Phase 321Phase 442Phase N / A18

Late-stage studies

Phase III+ trials still open or recently active — where late-stage evidence is being generated.

A Pilot Study of Low Dose Naltrexone Use in Patients With Postural Orthostatic Tachycardia Syndrome

Not yet recruitingPH IVUniversity of Calgaryn=802030

Sex Differences in Trauma, Inflammation and Brain Function and the Implications for Treatment Efficacy in Alcohol Use Disorder

RecruitingPH IVMilky Kohnon=1002028

Low Dose Naltrexone (LDN) for the Treatment of Chronic Neuropathic Pain in Patients With Human Immunodeficiency Virus (HIV), a Prospective, Pragmatic, Open Label Clinical Trial

RecruitingPH IVEmory Universityn=602027

Low Dose Naltrexone (LDN) Therapy for Complex Regional Pain Syndrome (CRPS): A Feasibility Study

Enrolling by invitationPH IVHospital for Special Surgery, New Yorkn=402026

Neurocomputational Mechanisms of Mood Improvement

CompletedPH IVMarta Peciña, MD PhDn=1202026

Recent completions

Trials that read out recently, adding to the completed evidence base.

Targeted Naltrexone to Support Individuals Participating in Dry January

CompletedPH IIBrigham and Women's Hospitaln=192026

Neurocomputational Mechanisms of Mood Improvement

CompletedPH IVMarta Peciña, MD PhDn=1202026

A Double Blind Randomized Trial of Low-dose Naltrexone for Post-COVID Fatigue Syndrome

CompletedPH IILuis Naculn=1602026

Low Dose Naltrexone to Improve Physical Health in Patients With Vasculitis

CompletedPH IIUniversity of Pennsylvanian=602025

The ION+EMI Study: Intermittent Oral Naltrexone Enhanced With an Ecological Momentary Intervention for Methamphetamine-using MSM

CompletedPH IIGlenn-Milo Santosn=602024

The Mechanism of Human Non-Shivering Thermogenesis and Basal Metabolic Rate

CompletedPH IINational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)n=472024

Research activity

8 papers

Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.

Publications over time

20062023

Most influential

Gabapentin combined with naltrexone for the treatment of alcohol dependence.

The American journal of psychiatry · 2011 · 95 cites

Association of OPRM1 A118G variant with the relative reinforcing value of nicotine.

Psychopharmacology · 2006 · 95 cites

Naltrexone vs Placebo for the Treatment of Alcohol Dependence: A Randomized Clinical Trial.

JAMA psychiatry · 2015 · 87 cites

Naltrexone for impulse control disorders in Parkinson disease: a placebo-controlled study.

Neurology · 2014 · 78 cites

Randomized, proof-of-concept trial of low dose naltrexone for patients with breakthrough symptoms of major depressive disorder on antidepressants.

Journal of affective disorders · 2017 · 41 cites

Naltrexone/bupropion for binge-eating disorder: A randomized, double-blind, placebo-controlled trial.

Obesity (Silver Spring, Md.) · 2023 · 40 cites

Related drugs

1 matches

Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).

Bupropion

Studied across 4 of the same disease areas as Naltrexone in the shared literature.

4 shared diseases1 shared paper

References & data sources

RxNorm (U.S. National Library of Medicine) — drug identity
ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
Europe PMC — research literature
ClinicalTrials.gov — clinical trials